Cargando…

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility

AIM/PURPOSE: (18)F-labeled PSMA ligands offer various advantages as PET tracers over (68)Ga-labeled PSMA counterparts. Especially, an improved spatial resolution leads to improved detection rates of smaller prostate cancer (PCa) lesions. However, physiological PSMA uptake of ganglia of the sympathet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mamlins, E., Schmitt, D., Beu, M., Mattes-György, K., Henke, J. M., Antke, C., Novruzov, E., Cardinale, J., Kirchner, J., Niegisch, G., Radtke, J. P., Schimmöller, L., Albers, P., Antoch, G., Giesel, F. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172258/ https://www.ncbi.nlm.nih.gov/pubmed/36369484 http://dx.doi.org/10.1007/s11307-022-01784-4

Ejemplares similares

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

Unique [(18)F]FDG PET imaging pattern of drug-induced acute generalized exanthematous pustulosis within the SCAR-spectrum
por: Novruzov, E., et al.
Publicado: (2022)

Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body (68) Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?
por: Morawitz, Janna, et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
por: Naka, Sadahiro, et al.
Publicado: (2020)

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
por: Watabe, Tadashi, et al.
Publicado: (2021)

Serotonergic Modulation of Nigrostriatal and Mesolimbic Dopamine and Motor/Exploratory Behaviors in the Rat
por: Nikolaus, Susanne, et al.
Publicado: (2021)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer
por: Novruzov, E., et al.
Publicado: (2022)

Detecting and Locating the Site of Local Relapse Using (18)F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
por: Koerber, S. A., et al.
Publicado: (2022)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [(18)F]FAPI-74 with [(18)F]FDG in Patients with PDAC: A Prospective Exploratory Study
por: Novruzov, Emil, et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Differential effects of D-cycloserine and amantadine on motor behavior and D(2/3) receptor binding in the nigrostriatal and mesolimbic system of the adult rat
por: Nikolaus, Susanne, et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [(18)F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
por: Kim, Su Bin, et al.
Publicado: (2022)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Development of the sympathetic trunks in human embryos
por: Kruepunga, Nutmethee, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

[(18)F]PSMA‐1007 renal uptake parameters: Reproducibility and relationship to estimated glomerular filtration rate
por: Valind, Kristian, et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
por: Cardinale, Jens, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ob29f1hvmigm34i0ajk0q8v92g